FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 334:349-356 February 8, 1996 Number 6 Next

	Full Text PDF Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited Related Article PubMed Citation

ABSTRACT

Background Because of concern about safety and efficacy, no pertussis vaccine has been included in the vaccination program in Sweden since 1979. To provide data that might permit the reintroduction of a pertussis vaccine, we conducted a placebo-controlled trial of two acellular and one whole-cell pertussis vaccines.

Methods After informed consent was obtained, 9829 children born in 1992 were randomly assigned to receive one of four vaccines: a two-component acellular diphtheria–tetanus–pertussis (DTP) vaccine (2566 children), a five-component acellular DTP vaccine (2587 children), a whole-cell DTP vaccine licensed in the United States (2102 children), or (as a control) a vaccine containing diphtheria and tetanus toxoids (DT) alone (2574 children). The vaccines were given at 2, 4, and 6 months of age, and the children were then followed for signs of pertussis for an additional 2 years (to a mean age of 21/2 years).

Results the whole-cell vaccine was associated with significantly higher rates of protracted crying, cyanosis, fever, and local reactions than the other three vaccines. The rates of adverse events were similar for the acellular vaccines and the control DT vaccine. After three doses, the efficacy of the vaccines with respect to pertussis linked to a laboratory-confirmed case of pertussis or contact with an infected household member with paroxysmal cough for >21 days was 58.9 percent for the two-component vaccine (95 percent confidence interval, 50.9 to 65.9 percent), 85.2 percent for the five-component vaccine (95 percent confidence interval, 80.6 to 88.8 percent), and 48.3 percent for the whole-cell vaccine (95 percent confidence interval, 37.0 to 57.6 percent).

Conclusions The five-component acellular pertussis vaccine we evaluated can be recommended for general use, since it has a favorable safety profile and confers sustained protection against pertussis. The two-component acellular vaccine and the whole-cell vaccine were less efficacious.

Source Information

From Sachs' Children's Hospital (L.G., P.O., J.S.) and the Swedish Institute for Infectious Disease Control (H.O.H., P.O., E.R.) — both in Stockholm, Sweden.

Address reprint requests to Dr. Olin at the Swedish Institute for Infectious Disease Control, S-10521 Stockholm, Sweden.

Full Text of this Article

This article has been cited by other articles:

• Tejiokem, M. C., Njamkepo, E., Gouandjika, I., Rousset, D., Beniguel, L., Bilong, C., Tene, G., Penda, I., Ngongueu, C., Gody, J. C., Guiso, N., Baril, L. (2009). Whole-Cell Pertussis Vaccine Induces Low Antibody Levels in Human Immunodeficiency Virus-Infected Children Living in Sub-Saharan Africa. CVI 16: 479-483 [Abstract] [Full Text]  
• Zorzeto, T. Q., Higashi, H. G., da Silva, M. T. N., Carniel, E. d. F., Dias, W. O., Ramalho, V. D., Mazzola, T. N., Lima, S. C. B. S., Morcillo, A. M., Stephano, M. A., Antonio, M. A. R. d. G., Zanolli, M. d. L., Raw, I., Vilela, M. M. d. S. (2009). Immunogenicity of a Whole-Cell Pertussis Vaccine with Low Lipopolysaccharide Content in Infants. CVI 16: 544-550 [Abstract] [Full Text]  
• Stenger, R. M., Poelen, M. C. M., Moret, E. E., Kuipers, B., Bruijns, S. C. M., Hoogerhout, P., Hijnen, M., King, A. J., Mooi, F. R., Boog, C. J. P., van Els, C. A. C. M. (2009). Immunodominance in Mouse and Human CD4+ T-Cell Responses Specific for the Bordetella pertussis Virulence Factor P.69 Pertactin. Infect. Immun. 77: 896-903 [Abstract] [Full Text]  
• Guerra, F. A., Blatter, M. M., Greenberg, D. P., Pichichero, M., Noriega, F. R., on behalf of the Pentacel Study Group, (2009). Safety and Immunogenicity of a Pentavalent Vaccine Compared With Separate Administration of Licensed Equivalent Vaccines in US Infants and Toddlers and Persistence of Antibodies Before a Preschool Booster Dose: A Randomized, Clinical Trial. Pediatrics 123: 301-312 [Abstract] [Full Text]  
• Shinall, M. C. Jr, Peters, T. R., Zhu, Y., Chen, Q., Poehling, K. A. (2008). Potential Impact of Acceleration of the Pertussis Vaccine Primary Series for Infants. Pediatrics 122: 1021-1026 [Abstract] [Full Text]  
• Roy, K., Hamilton, D., Allen, K. P., Randolph, M. P., Fleckenstein, J. M. (2008). The EtpA Exoprotein of Enterotoxigenic Escherichia coli Promotes Intestinal Colonization and Is a Protective Antigen in an Experimental Model of Murine Infection. Infect. Immun. 76: 2106-2112 [Abstract] [Full Text]  
• Fry, S. R., Chen, A. Y., Daggard, G., Mukkur, T. K. S. (2008). Parenteral immunization of mice with a genetically inactivated pertussis toxin DNA vaccine induces cell-mediated immunity and protection. J Med Microbiol 57: 28-35 [Abstract] [Full Text]  
• Aase, A., Herstad, T. K., Merino, S., Brandsdal, K. T., Berdal, B. P., Aleksandersen, E. M., Aaberge, I. S. (2007). Opsonophagocytic Activity and Other Serological Indications of Bordetella pertussis Infection in Military Recruits in Norway. CVI 14: 855-862 [Abstract] [Full Text]  
• Higgins, S. C., Jarnicki, A. G., Lavelle, E. C., Mills, K. H. G. (2006). TLR4 Mediates Vaccine-Induced Protective Cellular Immunity to Bordetella pertussis: Role of IL-17-Producing T Cells. J. Immunol. 177: 7980-7989 [Abstract] [Full Text]  
• Vickers, D., Ross, A. G., Mainar-Jaime, R. C., Neudorf, C., Shah, S. (2006). Whole-cell and acellular pertussis vaccination programs and rates of pertussis among infants and young children.. CMAJ 175: 1213-1217 [Abstract] [Full Text]  
• Halperin, S. A., De Serres, G. (2006). Has the change to acellular pertussis vaccine improved or worsened pertussis control?. CMAJ 175: 1227-1227 [Full Text]  
• Elahi, S., Buchanan, R. M., Babiuk, L. A., Gerdts, V. (2006). Maternal Immunity Provides Protection against Pertussis in Newborn Piglets.. Infect. Immun. 74: 2619-2627 [Abstract] [Full Text]  
• Committee on Infectious Diseases, (2006). Prevention of Pertussis Among Adolescents: Recommendations for Use of Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis (Tdap) Vaccine. Pediatrics 117: 965-978 [Abstract] [Full Text]  
• Galanis, E., King, A. S., Varughese, P., Halperin, S. A. (2006). Changing epidemiology and emerging risk groups for pertussis.. CMAJ 174: 451-452 [Full Text]  
• Niedziela, T., Letowska, I., Lukasiewicz, J., Kaszowska, M., Czarnecka, A., Kenne, L., Lugowski, C. (2005). Epitope of the Vaccine-Type Bordetella pertussis Strain 186 Lipooligosaccharide and Antiendotoxin Activity of Antibodies Directed against the Terminal Pentasaccharide-Tetanus Toxoid Conjugate. Infect. Immun. 73: 7381-7389 [Abstract] [Full Text]  
• Halperin, S. A. (2005). Pertussis--a disease and vaccine for all ages.. NEJM 353: 1615-1617 [Full Text]  
• Poland, G. A. (2005). The Growing Paradigm of Preventing Disease: Vaccines To Prevent Herpes Zoster and Pertussis in Adults. ANN INTERN MED 143: 539-541 [Full Text]  
• Bisgard, K. M., Rhodes, P., Connelly, B. L., Bi, D., Hahn, C., Patrick, S., Glode, M. P., Ehresmann, K. R., and the Pertussis Investigation Team, (2005). Pertussis Vaccine Effectiveness Among Children 6 to 59 Months of Age in the United States, 1998-2001. Pediatrics 116: e285-e294 [Abstract] [Full Text]  
• Pichichero, M. E., Rennels, M. B., Edwards, K. M., Blatter, M. M., Marshall, G. S., Bologa, M., Wang, E., Mills, E. (2005). Combined Tetanus, Diphtheria, and 5-Component Pertussis Vaccine for Use in Adolescents and Adults. JAMA 293: 3003-3011 [Abstract] [Full Text]  
• van Amersfoorth, S. C. M., Schouls, L. M., van der Heide, H. G. J., Advani, A., Hallander, H. O., Bondeson, K., von Konig, C. H. W., Riffelmann, M., Vahrenholz, C., Guiso, N., Caro, V., Njamkepo, E., He, Q., Mertsola, J., Mooi, F. R. (2005). Analysis of Bordetella pertussis Populations in European Countries with Different Vaccination Policies. J. Clin. Microbiol. 43: 2837-2843 [Abstract] [Full Text]  
• Hallander, H. O., Advani, A., Donnelly, D., Gustafsson, L., Carlsson, R.-M. (2005). Shifts of Bordetella pertussis Variants in Sweden from 1970 to 2003, during Three Periods Marked by Different Vaccination Programs. J. Clin. Microbiol. 43: 2856-2865 [Abstract] [Full Text]  
• Cherry, J. D. (2005). The Epidemiology of Pertussis: A Comparison of the Epidemiology of the Disease Pertussis With the Epidemiology of Bordetella pertussis Infection. Pediatrics 115: 1422-1427 [Abstract] [Full Text]  
• Mattoo, S., Cherry, J. D. (2005). Molecular Pathogenesis, Epidemiology, and Clinical Manifestations of Respiratory Infections Due to Bordetella pertussis and Other Bordetella Subspecies. Clin. Microbiol. Rev. 18: 326-382 [Abstract] [Full Text]  
• Tozzi, A. E., Pastore Celentano, L., Ciofi degli Atti, M. L., Salmaso, S. (2005). Diagnosis and management of pertussis. CMAJ 172: 509-515 [Abstract] [Full Text]  
• Baughman, A. L., Bisgard, K. M., Edwards, K. M., Guris, D., Decker, M. D., Holland, K., Meade, B. D., Lynn, F. (2004). Establishment of Diagnostic Cutoff Points for Levels of Serum Antibodies to Pertussis Toxin, Filamentous Hemagglutinin, and Fimbriae in Adolescents and Adults in the United States. CVI 11: 1045-1053 [Abstract] [Full Text]  
• Hijnen, M., Mooi, F. R., van Gageldonk, P. G. M., Hoogerhout, P., King, A. J., Berbers, G. A. M. (2004). Epitope Structure of the Bordetella pertussis Protein P.69 Pertactin, a Major Vaccine Component and Protective Antigen. Infect. Immun. 72: 3716-3723 [Abstract] [Full Text]  
• Advani, A., Donnelly, D., Hallander, H. (2004). Reference System for Characterization of Bordetella pertussis Pulsed-Field Gel Electrophoresis Profiles. J. Clin. Microbiol. 42: 2890-2897 [Abstract] [Full Text]  
• Nilsson, L., Kjellman, N.-I. M., Bjorksten, B. (2003). Allergic Disease at the Age of 7 Years After Pertussis Vaccination in Infancy: Results From the Follow-up of a Randomized Controlled Trial of 3 Vaccines. Arch Pediatr Adolesc Med 157: 1184-1189 [Abstract] [Full Text]  
• Skowronski, D. M., Remple, V. P., Macnabb, J., Pielak, K., Patrick, D. M., Halperin, S. A., Scheifele, D. (2003). Injection-Site Reactions to Booster Doses of Acellular Pertussis Vaccine: Rate, Severity, and Anticipated Impact. Pediatrics 112: e453-459 [Abstract] [Full Text]  
• Le Saux, N., Barrowman, N. J., Moore, D. L., Whiting, S., Scheifele, D., Halperin, S., for Members of the Canadian Paediatric Society/ He, (2003). Decrease in Hospital Admissions for Febrile Seizures and Reports of Hypotonic-Hyporesponsive Episodes Presenting to Hospital Emergency Departments Since Switching to Acellular Pertussis Vaccine in Canada: A Report From IMPACT. Pediatrics 112: e348-348 [Abstract] [Full Text]  
• Cohn, J. N (2003). Interaction of -blockers and angiotensin receptor blockers/ACE inhibitors in heart failure. Journal of Renin-Angiotensin-Aldosterone System 4: 137-139 [Abstract]  
• Cherry, J. D. (2003). The Science and Fiction of the "Resurgence" of Pertussis. Pediatrics 112: 405-406 [Full Text]  
• Bruss, J. B., Siber, G. R. (2002). Quantitative Priming with Inactivated Pertussis Toxoid Vaccine in the Aerosol Challenge Model. Infect. Immun. 70: 4600-4608 [Abstract] [Full Text]  
• Roduit, C., Bozzotti, P., Mielcarek, N., Lambert, P.-H., del Giudice, G., Locht, C., Siegrist, C.-A. (2002). Immunogenicity and Protective Efficacy of Neonatal Vaccination against Bordetella pertussis in a Murine Model: Evidence for Early Control of Pertussis. Infect. Immun. 70: 3521-3528 [Abstract] [Full Text]  
• SHINA, A., HART, C. A., STENTON, M. D., DAWSON, S., MCCRACKEN, C. M., BINNS, S. H., GASKELL, R. M., WINSTANLEY, C. (2002). Distribution of fim3 and flaA TTGE sequence types amongst isolates of Bordetella bronchiseptica from different host animals. J Med Microbiol 51: 557-587 [Abstract] [Full Text]  
• Canthaboo, C., Xing, D., Wei, X. Q., Corbel, M. J. (2002). Investigation of Role of Nitric Oxide in Protection from Bordetella pertussis Respiratory Challenge. Infect. Immun. 70: 679-684 [Abstract] [Full Text]  
• Salmaso, S., Mastrantonio, P., Tozzi, A. E., Stefanelli, P., Anemona, A., Atti, M. L. C. d., Giammanco, A., the Stage III Working Group, (2001). Sustained Efficacy During the First 6 Years of Life of 3-Component Acellular Pertussis Vaccines Administered in Infancy: The Italian Experience. Pediatrics 108: e81-81 [Abstract] [Full Text]  
• Donnelly, S., Loscher, C. E., Lynch, M. A., Mills, K. H. G. (2001). Whole-Cell but Not Acellular Pertussis Vaccines Induce Convulsive Activity in Mice: Evidence of a Role for Toxin-Induced Interleukin-1{beta} in a New Murine Model for Analysis of Neuronal Side Effects of Vaccination. Infect. Immun. 69: 4217-4223 [Abstract] [Full Text]  
• Liese, J. G., Belohradsky, B. H., Walker;, A. M., Cherry, J. D., Olin, P. (2001). The Science and Fiction of Pertussis Vaccines. Pediatrics 107: 611-612 [Full Text]  
• Tozzi, A. E., Anemona, A., Stat, D., Stefanelli, P., Biol, D., Salmaso, S., Biol, D., Atti, M. L. C. d., Mastrantonio, P., Giammanco, A., the Progetto Pertosse Study Group, (2001). Reactogenicity and Immunogenicity at Preschool Age of a Booster Dose of Two Three-Component Diphtheria-Tetanus-Acellular Pertussis Vaccines in Children Primed in Infancy With Acellular Vaccines. Pediatrics 107: 25e-25 [Abstract] [Full Text]  
• Braun, M. M., Mootrey, G. T., Salive, M. E., Chen, R. T., Ellenberg, S. S., the VAERS Working Group, (2000). Infant Immunization With Acellular Pertussis Vaccines in the United States: Assessment of the First Two Years' Data From the Vaccine Adverse Event Reporting System (VAERS). Pediatrics 106: 51e-51 [Abstract] [Full Text]  
• Ellenberg, S. S., Temple, R. (2000). Placebo-Controlled Trials and Active-Control Trials in the Evaluation of New Treatments. Part 2: Practical Issues and Specific Cases. ANN INTERN MED 133: 464-470 [Abstract] [Full Text]  
• Ekwueme, D. U., Strebel, P. M., Hadler, S. C., Meltzer, M. I., Allen, J. W., Livengood, J. R. (2000). Economic Evaluation of Use of Diphtheria, Tetanus, and Acellular Pertussis Vaccine or Diphtheria, Tetanus, and Whole-Cell Pertussis Vaccine in the United States, 1997. Arch Pediatr Adolesc Med 154: 797-803 [Abstract] [Full Text]  
• Rowe, J., Macaubas, C., Monger, T. M., Holt, B. J., Harvey, J., Poolman, J. T., Sly, P. D., Holt, P. G. (2000). Antigen-Specific Responses to Diphtheria-Tetanus-Acellular Pertussis Vaccine in Human Infants Are Initially Th2 Polarized. Infect. Immun. 68: 3873-3877 [Abstract] [Full Text]  
• Leef, M., Elkins, K. L., Barbic, J., Shahin, R. D. (2000). Protective Immunity to Bordetella pertussis Requires Both B Cells and Cd4+ T Cells for Key Functions Other than Specific Antibody Production. JEM 191: 1841-1852 [Abstract] [Full Text]  
• Hausman, S. Z., Burns, D. L. (2000). Use of Pertussis Toxin Encoded by ptx Genes from Bordetella bronchiseptica To Model the Effects of Antigenic Drift of Pertussis Toxin on Antibody Neutralization. Infect. Immun. 68: 3763-3767 [Abstract] [Full Text]  
• Gilbert, P. B (2000). Some statistical issues in the design of HIV-1 vaccine and treatment trials. Stat Methods Med Res 9: 207-229 [Abstract]  
• Kosters, K., Riffelmann, M., Dohrn, B., von Konig, C. H. W. (2000). Comparison of Five Commercial Enzyme-Linked Immunosorbent Assays for Detection of Antibodies to Bordetella pertussis. CVI 7: 422-426 [Abstract] [Full Text]  
• Mattoo, S., Miller, J. F., Cotter, P. A. (2000). Role of Bordetella bronchiseptica Fimbriae in Tracheal Colonization and Development of a Humoral Immune Response. Infect. Immun. 68: 2024-2033 [Abstract] [Full Text]  
• McGuirk, P., Mills, K. H. G. (2000). A Regulatory Role for Interleukin 4 in Differential Inflammatory Responses in the Lung following Infection of Mice Primed with Th1- or Th2-Inducing Pertussis Vaccines. Infect. Immun. 68: 1383-1390 [Abstract] [Full Text]  
• Heininger, U., Schmidt-Schläpfer, G., Cherry, J. D., Stehr, K. (2000). Clinical Validation of a Polymerase Chain Reaction Assay for the Diagnosis of Pertussis by Comparison With Serology, Culture, and Symptoms During a Large Pertussis Vaccine Efficacy Trial. Pediatrics 105: 31e-31 [Abstract] [Full Text]  
• Nygren, M., Reizenstein, E., Ronaghi, M., Lundeberg, J. (2000). Polymorphism in the Pertussis Toxin Promoter Region Affecting the DNA-Based Diagnosis of Bordetella Infection. J. Clin. Microbiol. 38: 55-60 [Abstract] [Full Text]  
• Ryan, E. J., McNeela, E., Murphy, G. A., Stewart, H., O'hagan, D., Pizza, M., Rappuoli, R., Mills, K. H. G. (1999). Mutants of Escherichia coli Heat-Labile Toxin Act as Effective Mucosal Adjuvants for Nasal Delivery of an Acellular Pertussis Vaccine: Differential Effects of the Nontoxic AB Complex and Enzyme Activity on Th1 and Th2 Cells. Infect. Immun. 67: 6270-6280 [Abstract] [Full Text]  
• Cherry, J. D., Olin, P. (1999). The Science and Fiction of Pertussis Vaccines. Pediatrics 104: 1381-1383 [Full Text]  
• Abomoelak, B., Huygen, K., Kremer, L., Turneer, M., Locht, C. (1999). Humoral and Cellular Immune Responses in Mice Immunized with Recombinant Mycobacterium bovis Bacillus Calmette-Guerin Producing a Pertussis Toxin-Tetanus Toxin Hybrid Protein. Infect. Immun. 67: 5100-5105 [Abstract] [Full Text]  
• Salmaso, S., Tozzi, A. E., Atti;, M. L. C. d., Cherry, J. D. (1999). Observer Bias in Acellular Pertussis Vaccine Trials. Pediatrics 104: 997-997 [Full Text]  
• Bruss, J. B., Siber, G. R. (1999). Protective Effects of Pertussis Immunoglobulin (P-IGIV) in the Aerosol Challenge Model. CVI 6: 464-470 [Abstract] [Full Text]  
• Lee, C.-Y., Thipphawong, J., Huang, L.-M., Lee, P.-I., Chiu, H.-H., Lin, W., Debois, H., Harrison, D., Xie, F., Barreto, L. (1999). An Evaluation of the Safety and Immunogenicity of a Five-Component Acellular Pertussis, Diphtheria, and Tetanus Toxoid Vaccine (DTaP) When Combined With a Haemophilus influenzae Type b-Tetanus Toxoid Conjugate Vaccine (PRP-T) in Taiwanese Infants. Pediatrics 103: 25-30 [Abstract] [Full Text]  
• Cherry, J. D., Heininger, U., Stehr, K., Christenson, P. (1998). The Effect of Investigator Compliance (Observer Bias) on Calculated Efficacy in a Pertussis Vaccine Trial. Pediatrics 102: 909-912 [Abstract] [Full Text]  
• Heininger, U., Cherry, J. D., Stehr, K., Schmitt-Grohe, S., Uberall, M., Laussucq, S., Eckhardt, T., Meyer, M., Gornbein, J., the Pertussis Vaccine Study Group, (1998). Comparative Efficacy of the Lederle/Takeda Acellular Pertussis Component DTP (DTaP) Vaccine and Lederle Whole-Cell Component DTP Vaccine in German Children After Household Exposure. Pediatrics 102: 546-553 [Abstract] [Full Text]  
• He, Q., Minh, N. N. T., Edelman, K., Viljanen, M. K., Arvilommi, H., Mertsola, J. (1998). Cytokine mRNA Expression and Proliferative Responses Induced by Pertussis Toxin, Filamentous Hemagglutinin, and Pertactin of Bordetella pertussis in the Peripheral Blood Mononuclear Cells of Infected and Immunized Schoolchildren and Adults. Infect. Immun. 66: 3796-3801 [Abstract] [Full Text]  
• Nilsson, L., Kjellman, N.-I. M., Bjorksten, B. (1998). A Randomized Controlled Trial of the Effect of Pertussis Vaccines on Atopic Disease. Arch Pediatr Adolesc Med 152: 734-738 [Abstract] [Full Text]  
• Mastrantonio, P., Stefanelli, P., Giuliano, M., Rojas, Y. H., Ciofi degli Atti, M., Anemona, A., Tozzi, A. E. (1998). Bordetella parapertussis Infection in Children: Epidemiology, Clinical Symptoms, and Molecular Characteristics of Isolates. J. Clin. Microbiol. 36: 999-1002 [Abstract] [Full Text]  
• Poulain-Godefroy, O., Mielcarek, N., Ivanoff, N., Remoue, F., Schacht, A.-M., Phillips, N., Locht, C., Capron, A., Riveau, G. (1998). Bordetella pertussis Filamentous Hemagglutinin Enhances the Immunogenicity of Liposome-Delivered Antigen Administered Intranasally. Infect. Immun. 66: 1764-1767 [Abstract] [Full Text]  
• Simondon, F., Iteman, I., Preziosi, M. P., Yam, A., Guiso, N. (1998). Evaluation of an Immunoglobulin G Enzyme-Linked Immunosorbent Assay for Pertussis Toxin and Filamentous Hemagglutinin in Diagnosis of Pertussis in Senegal. CVI 5: 130-134 [Abstract] [Full Text]  
• Mills, K. H. G., Ryan, M., Ryan, E., Mahon, B. P. (1998). A Murine Model in Which Protection Correlates with Pertussis Vaccine Efficacy in Children Reveals Complementary Roles for Humoral and Cell-Mediated Immunity in Protection against Bordetella pertussis. Infect. Immun. 66: 594-602 [Abstract] [Full Text]  
• Edwards, K., Adam, H. M. (1998). Acellular Pertussis Vaccines. Pediatr. Rev. 19: 68-70 [Full Text]  
• Stehr, K., Cherry, J. D., Heininger, U., Schmitt-Grohe, S., Uberall, M., Laussucq, S., Eckhardt, T., Meyer, M., Engelhardt, R., Christenson, P., the Pertussis Vaccine Study Group, (1998). A Comparative Efficacy Trial in Germany in Infants Who Received Either the Lederle/Takeda Acellular Pertussis Component DTP (DTaP) Vaccine, the Lederle Whole-Cell Component DTP Vaccine, or DT Vaccine. Pediatrics 101: 1-11 [Abstract] [Full Text]  
• Mahon, B. P., Sheahan, B. J., Griffin, F., Murphy, G., Mills, K. H.G. (1997). Atypical Disease after Bordetella pertussis Respiratory Infection of Mice with Targeted Disruptions of Interferon-{gamma} Receptor or Immunoglobulin {micro} Chain Genes. JEM 186: 1843-1851 [Abstract] [Full Text]  
• Pichichero, M. E., Deloria, M. A., Rennels, M. B., Anderson, E. L., Edwards, K. M., Decker, M. D., Englund, J. A., Steinhoff, M. C., Deforest, A., Meade, B. D. (1997). A Safety and Immunogenicity Comparison of 12 Acellular Pertussis Vaccines and One Whole-Cell Pertussis Vaccine Given as a Fourth Dose in 15- to 20-Month-Old Children. Pediatrics 100: 772-788 [Abstract] [Full Text]  
• Cassone, A., Ausiello, C. M., Urbani, F., Lande, R., Giuliano, M., La Sala, A., Piscitelli, A., Salmaso, S. (1997). Cell-mediated and Antibody Responses to Bordetella pertussis Antigens in Children Vaccinated With Acellular or Whole-cell Pertussis Vaccines. Arch Pediatr Adolesc Med 151: 283-289 [Abstract]  
• Committee on Infectious Diseases, (1997). Acellular Pertussis Vaccine: Recommendations for Use as the Initial Series in Infants and Children. Pediatrics 99: 282-288 [Abstract] [Full Text]  
• Pichichero, M. E., Treanor, J. (1997). Economic Impact of Pertussis. Arch Pediatr Adolesc Med 151: 35-40 [Abstract]  
• Rosenthal, S., Chen, R. T., Hadler, S. (1997). Reputed Brain Damage and 'Serious' Reactions From DTP Vaccines-Reply. Arch Pediatr Adolesc Med 151: 108-108 [Abstract]  
• Sepkowitz, S. (1997). Reputed Brain Damage and 'Serious' Reactions From DTP Vaccines. Arch Pediatr Adolesc Med 151: 107-108 [Abstract]  
• Mollnes, T. E., Harboe, M. (1996). Recent Advances: Clinical immunology. BMJ 312: 1465-1469 [Abstract] [Full Text]  
• Levine, M. M (1996). The legacy of Edward Jenner. BMJ 312: 1177-1178 [Full Text]  
• (1996). National, State, and Urban Area Vaccination Coverage Levels Among Children Aged 19-35 Months--United States, April 1994-March 1995. JAMA 275: 828-829  
• Nilsson, L., Kjellman, N.-I. M., Storsaeter, J., Olin, P. (1996). Lack of Association Between Pertussis Vaccination and Symptoms of Asthma and Allergy. JAMA 275: 760-760 [Abstract]  
• (1996). ACELLULAR PERTUSSIS VACCINE: A NEW ERA FOR INFANTS. JWatch General 1996: 5-5 [Full Text]  
• Greco, D., Salmaso, S., Mastrantonio, P., Giuliano, M., Tozzi, A. E., Anemona, A., Ciofi degli Atti, M. L., Giammanco, A., Panei, P., Blackwelder, W. C., Klein, D. L., Wassilak, S. G.F., The Progetto Pertosse Working Group, (1996). A Controlled Trial of Two Acellular Vaccines and One Whole-Cell Vaccine against Pertussis. NEJM 334: 341-349 [Abstract] [Full Text]  
• Edwards, K. M., Decker, M. D. (1996). Acellular Pertussis Vaccines for Infants. NEJM 334: 391-392 [Full Text]  
• Ellenberg, S. S., Foulkes, M. A., Midthun, K., Goldenthal, K. L. (2005). Evaluating the Safety of New Vaccines: Summary of a Workshop. AJPH 95: 800-807 [Abstract] [Full Text]